ClinicalTrials.gg
CompletedNCT03568331Updated May 13, 2024Results posted

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)

A Phase 3 interventional study of Tradipitant and Placebo in Atopic Dermatitis, sponsored by Vanda Pharmaceuticals. Completed at 70 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Vanda Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
92nd of 544
375 · median 96
Started
2018
with 55 others
Phase 3
103 of 639
8 open now
Registered
269th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 92nd largest by enrollment of the 544 interventional ones that give a count, is one of 56 that started in 2018, is one of 103 in phase 3, and was the 269th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Chronic Pruritus
  • Eczema
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and non-pregnant, non-lactating female patients aged 18 - 70 years (inclusive);
  • Diagnosed with atopic dermatitis;
  • Suffering from chronic pruritus;
  • (BMI) of ≥18 and ≤40 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Chronic pruritus due to condition other than atopic dermatitis (AD);
  • A positive test for drugs of abuse at the screening or evaluation visits;
  • Exposure to any medication in the past 8 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    Tradipitant

    Drug: Tradipitant

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Reduction of Worst Itch in Atopic Dermatitis

    Reduction of worst itch in atopic dermatitis as measured by Numerical Rating Scale (NRS). Worst Itch NRS is an assessment tool that is used to report the maximum intensity of participant's itch during a 24-hour recall period. Participants were asked the following question: Please rate the itching severity that describes your worst level of itching in the past 24 hours \[0=No Itch, 10=Worst Itch Imaginable\].

    Time frame: 8 weeks

Secondary outcomes

  1. Improvement of Disease Severity in Atopic Dermatitis

    Proportion of participants achieving 50% reduction on the SCORing Atopic Dermatitis (SCORAD) index. SCORAD is an assessment scale used to determine the severity of AD. SCORAD combines the investigator's rating of extent and intensity and the patient reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: 8 weeks

  2. Proportion of Patients With Improvement on Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of at Least 2-point Reduction

    As measured by the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). IGA is an assessment scale used to determine severity of AD. It is assessed by the investigator on a 5-point scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) based on erythema, induration/papulation, lichenification, and oozing/crusting.

    Time frame: 8 weeks

07

Results

Posted May 13, 2024

Participant flow

Participant flow — Overall Study
MilestoneTradipitantPlacebo
Started188187
Completed142144
Not completed4643

Outcome measures

PrimaryReduction of Worst Itch in Atopic Dermatitis

Reduction of worst itch in atopic dermatitis as measured by Numerical Rating Scale (NRS). Worst Itch NRS is an assessment tool that is used to report the maximum intensity of participant's itch during a 24-hour recall period. Participants were asked the following question: Please rate the itching severity that describes your worst level of itching in the past 24 hours \[0=No Itch, 10=Worst Itch Imaginable\].

Time frame:
8 weeks
Reported as:
Mean · units on a scale
Reduction of Worst Itch in Atopic Dermatitis
units on a scaleTradipitantPlacebo
Reduction of Worst Itch in Atopic Dermatitis-3.6 ± 2.8-3.5 ± 2.75
SecondaryImprovement of Disease Severity in Atopic Dermatitis

Proportion of participants achieving 50% reduction on the SCORing Atopic Dermatitis (SCORAD) index. SCORAD is an assessment scale used to determine the severity of AD. SCORAD combines the investigator's rating of extent and intensity and the patient reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Improvement of Disease Severity in Atopic Dermatitis
ParticipantsTradipitantPlacebo
Improvement of Disease Severity in Atopic Dermatitis5154
SecondaryProportion of Patients With Improvement on Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of at Least 2-point Reduction

As measured by the validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD). IGA is an assessment scale used to determine severity of AD. It is assessed by the investigator on a 5-point scale (0=clear, 1=almost clear, 2=mild, 3=moderate, 4=severe) based on erythema, induration/papulation, lichenification, and oozing/crusting.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Proportion of Patients With Improvement on Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of at Least 2-point Reduction
ParticipantsTradipitantPlacebo
Proportion of Patients With Improvement on Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of at Least 2-point Reduction3736
Post-hocReduction of Worst Itch in Atopic Dermatitis as Measured by Numerical Rating Scale (NRS), Adjusted for Investigator Global Assessment (IGA)

Worst Itch NRS is an assessment tool that is used to report the maximum intensity of participant's itch during a 24-hour recall period. Participants were asked the following question: Please rate the itching severity that describes your worst level of itching in the past 24 hours \[0=No Itch, 10=Worst Itch Imaginable\].

Time frame:
2 weeks
Reported as:
Mean · units on a scale
Reduction of Worst Itch in Atopic Dermatitis as Measured by Numerical Rating Scale (NRS), Adjusted for Investigator Global Assessment (IGA)
units on a scaleTradipitantPlacebo
Reduction of Worst Itch in Atopic Dermatitis as Measured by Numerical Rating Scale (NRS), Adjusted for Investigator Global Assessment (IGA)-2.6 (-3.2 to -2.0)-1.0 (-1.6 to -0.4)
Post-hocReduction in Sleep Disturbances as Measured by SCORing Atopic Dermatitis Index, Adjusted for Investigator Global Assessment

SCORAD is an assessment scale used to determine the severity of AD. SCORAD combines the investigator's rating of extent and intensity and the patient reported itch and sleep disturbance. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
2 weeks
Reported as:
Mean · units on a scale
Reduction in Sleep Disturbances as Measured by SCORing Atopic Dermatitis Index, Adjusted for Investigator Global Assessment
units on a scaleTradipitantPlacebo
Reduction in Sleep Disturbances as Measured by SCORing Atopic Dermatitis Index, Adjusted for Investigator Global Assessment-2.07 (-2.61 to -1.53)-0.7 (-1.24 to -0.15)

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent up to the final visit (Week 8) regardless of seriousness or relationship to investigational product. Patients with non-serious AEs that are ongoing at the patient's last study visit must be followed until resolution or for 30 days after the patient's last study visit, whichever comes first.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tradipitant0/188 (0%)2/188 (1.1%)23/188 (12.2%)
Placebo0/187 (0%)1/187 (0.5%)11/187 (5.9%)
Most frequent serious events
Most frequent serious events
EventTradipitantPlacebo
Extradural abscessInfections and infestations0/1881/187
ChokingRespiratory, thoracic and mediastinal disorders1/1880/187
Dyshidrotic eczemaSkin and subcutaneous tissue disorders1/1880/187
Most frequent other events
Most frequent other events
EventTradipitantPlacebo
Upper respiratory tract infectionInfections and infestations7/1884/187
HeadacheNervous system disorders7/1885/187
DiarrhoeaGastrointestinal disorders5/1881/187
Dermatitis atopicSkin and subcutaneous tissue disorders4/1881/187

Baseline characteristics

Age, Continuous
Age, Continuous(years)TradipitantPlaceboTotal
Mean41.7 ± 14.941.9 ± 15.141.8 ± 15.0
Sex: Female, Male
Sex: Female, Male(Participants)TradipitantPlaceboTotal
Female124119243
Male6468132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TradipitantPlaceboTotal
Hispanic or Latino424688
Not Hispanic or Latino144140284
Unknown or Not Reported213
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)TradipitantPlaceboTotal
Race — American Indian or Alaska Native000
Race — Asian101222
Race — Black or African American514596
Race — Native Hawaiian or Other Pacific Islander134
Race — White123123246
Race — Other347
Region of Enrollment
Region of Enrollment(Participants)TradipitantPlaceboTotal
United States188187375
Worst Itch Numeric Rating Scale (NRS) Score
Worst Itch Numeric Rating Scale (NRS) Score(units on a scale)TradipitantPlaceboTotal
Mean8.2 ± 1.28.1 ± 1.38.2 ± 1.3
SCORing Atopic Dermatitis (SCORAD) Index
SCORing Atopic Dermatitis (SCORAD) Index(units on a scale)TradipitantPlaceboTotal
Mean49.56 ± 14.550.76 ± 14.050.16 ± 14.3
Validated Investigator's Global Assessment scale for atopic dermatitis (vIGA-AD) Score
Validated Investigator's Global Assessment scale for atopic dermatitis (vIGA-AD) Score(Participants)TradipitantPlaceboTotal
Almost Clear (1)202
Mild (2)383977
Moderate (3)113105218
Severe (4)182644
08

Study locations

70 sites
  • Vanda Investigational Site
    Birmingham, Alabama 35224, United States
  • Vanda Investigational Site
    Birmingham, Alabama 35233, United States
  • Vanda Investigational Site
    Tempe, Arizona 85283, United States
  • Vanda Investigational Site
    Encino, California 91436, United States
  • Vanda Investigational Site
    Fountain Valley, California 92708, United States
  • Vanda Investigational Site
    Fremont, California 94538, United States
  • Vanda Investigational Site
    Laguna Hills, California 92653, United States
  • Vanda Investigational Site
    Lomita, California 90717, United States
  • Vanda Investigational Site
    Long Beach, California 90806, United States
  • Vanda Investigational Site
    Los Angeles, California 90017, United States
  • Vanda Investigational Site
    Los Angeles, California 90036, United States
  • Vanda Investigational Site
    San Diego, California 92122, United States
  • Vanda Investigational Site
    Santa Monica, California 90404, United States
  • Vanda Investigational Site
    Denver, Colorado 80220, United States
  • Vanda Investigational Site
    Aventura, Florida 33180, United States
  • Vanda Investigational Site
    Clearwater, Florida 33756, United States
  • Vanda Investigational Site
    Fort Lauderdale, Florida 33306, United States
  • Vanda Investigational Site
    Hialeah, Florida 33016, United States
  • Vanda Investigational Site
    Miami, Florida 33126, United States
  • Vanda Investigational Site
    Miami, Florida 33137, United States
  • Vanda Investigational Site
    Miramar, Florida 33027, United States
  • Vanda Investigational Site
    Ormond Beach, Florida 32174, United States
  • Vanda Investigational Site
    South Miami, Florida 33143, United States
  • Vanda Investigational Site
    Tampa, Florida 33613, United States
  • Vanda Investigational Site
    Savannah, Georgia 31406, United States
  • Vanda Investigational Site
    Boise, Idaho 83704, United States
  • Vanda Investigational Site
    Normal, Illinois 61761, United States
  • Vanda Investigational Site
    Skokie, Illinois 60077, United States
  • Vanda Investigational Site
    Plainfield, Indiana 46168, United States
  • Vanda Investigational Site
    Crowley, Louisiana 70526, United States
  • Vanda Investigational Site
    Rockville, Maryland 20850, United States
  • Vanda Investigational Site
    Towson, Maryland 21204, United States
  • Vanda Investigational Site
    Beverly, Massachusetts 01915, United States
  • Vanda Investigational Site
    Brighton, Massachusetts 02135, United States
  • Vanda Investigational Site
    Fort Gratiot, Michigan 48059, United States
  • Vanda Investigational Site
    Saint Joseph, Missouri 64506, United States
  • Vanda Investigational Site
    Saint Louis, Missouri 63141, United States
  • Vanda Investigational Site
    Omaha, Nebraska 68144, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89106, United States
  • Vanda Investigational Site
    Las Vegas, Nevada 89119, United States
  • Vanda Investigational Site
    Berlin, New Jersey 08009, United States
  • Vanda Investigational Site
    Verona, New Jersey 07044, United States
  • Vanda Investigational Site
    Brooklyn, New York 11201, United States
  • Vanda Investigational Site
    New York, New York 10003, United States
  • Vanda Investigational Site
    New York, New York 10022, United States
  • Vanda Investigational Site
    New York, New York 10075, United States
  • Vanda Investigational Site
    Charlotte, North Carolina 28277, United States
  • Vanda Investigational Site
    High Point, North Carolina 27262, United States
  • Vanda Investigational Site
    Wilmington, North Carolina 28405, United States
  • Vanda Investigational Site
    Cincinnati, Ohio 45212, United States
  • Vanda Investigational Site
    Dayton, Ohio 45414, United States
  • Vanda Investigational Site
    Oklahoma City, Oklahoma 73112, United States
  • Vanda Investigational Site
    Tulsa, Oklahoma 74136, United States
  • Vanda Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Vanda Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Vanda Investigational Site
    Johnston, Rhode Island 02919, United States
  • Vanda Investigational Site
    North Charleston, South Carolina 29420, United States
  • Vanda Investigational Site
    Spartanburg, South Carolina 29301, United States
  • Vanda Investigational Site
    Chattanooga, Tennessee 37421, United States
  • Vanda Investigational Site
    Nashville, Tennessee 37211, United States
  • Vanda Investigational Site
    Dallas, Texas 75230, United States
  • Vanda Investigational Site
    Pflugerville, Texas 78660, United States
  • Vanda Investigational Site
    San Antonio, Texas 78213, United States
  • Vanda Investigational Site
    San Antonio, Texas 78218, United States
  • Vanda Investigational Site
    West Jordan, Utah 84088, United States
  • Vanda Investigational Site
    South Burlington, Vermont 05403, United States
  • Vanda Investigational Site
    Newport News, Virginia 23606, United States
  • Vanda Investigational Site
    Norfolk, Virginia 23507, United States
  • Vanda Investigational Site
    Richmond, Virginia 23233, United States
  • Vanda Investigational Site
    Spokane, Washington 99202, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2019, 17 months.

Results were first posted in May 2024, 4 years 4 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 17 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2018
First posted
Jun 26, 2018
StartActual
Jul 9, 2018
Primary completionActual
Dec 27, 2019
CompletionActual
Dec 27, 2019
Results first posted
May 13, 2024
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03568331
Responsible party
Sponsor
First posted
Jun 26, 2018
Start date
Jul 9, 2018
Primary completion
Dec 27, 2019
Completion
Dec 27, 2019
Results posted
May 13, 2024
Last update
May 13, 2024

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tradipitant

Start the discussion